Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a Phase 3 clinical trial registry record with no reported results; the study is active but not recruiting, and efficacy outcomes have not yet been posted.
This is a Phase 2 clinical trial registry record with no results posted; the study is currently recruiting and has not yet generated efficacy or safety data.
This is an ongoing Phase 3 trial registration with no results posted; the study is actively recruiting and has not yet reported efficacy or safety outcomes.
This is an ongoing observational registry record with no results posted; it describes a planned blood collection study to characterize tarlatamab pharmacology in real-world SCLC treatment.
Phase 3 randomized trial of ifinatamab deruxtecan versus physician's choice in relapsed SCLC; registry record with no results posted, so efficacy and safety remain unreported.